Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness from a randomised controlled trial

BACKGROUND: Simvastatin therapy for patients with acute respiratory distress syndrome (ARDS) has been shown to be safe and associated with minimal adverse effects, but it does not improve clinical outcomes. The aim of this research was to report on mortality and cost-effectiveness of simvastatin in...

Descripción completa

Detalles Bibliográficos
Autores principales: Agus, A., Hulme, C., Verghis, R. M., McDowell, C., Jackson, C., O’Kane, C. M., Laffey, J. G., McAuley, D. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434552/
https://www.ncbi.nlm.nih.gov/pubmed/28511660
http://dx.doi.org/10.1186/s13054-017-1695-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434552/
https://www.ncbi.nlm.nih.gov/pubmed/28511660
http://dx.doi.org/10.1186/s13054-017-1695-0

Ejemplares similares